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Purpose

34
New specific and sensitive disease endpoints are critically needed to alleviate roadblocks to 35 development of disease modifying therapeutics and strategies for secondary prevention of 36 osteoarthritis (OA). A key step in this process is the development of standardized definitions of 37 OA. Standardization of OA definitions would aid communication across the field and help 38 advance drug development for OA and research by achieving consensus on globally recognized 39 definitions of disease and globally recognized standards for classifying the disease. We 40 anticipate that these definitions could facilitate communication about the disease among 41 industry and non-industry researchers, regulatory agencies, funding agencies, third party 42 payers, and patients. We further anticipate that these definitions would be maintained by the 43 Osteoarthritis Research Society International (OARSI) and subjected to regular refinement as 44 new scientific advances demand. Definitions proposed are not intended to distinguish an OA 45 patient uniquely from patients with other forms of arthritis; rather, the draft definitions can be 46 viewed as the building blocks for defining OA phenotypes. We fully acknowledge that these 47 building blocks are likely most applicable to knee and hip OA, possibly helpful for hand OA, but 48 will require modification for spine OA. In this review we therefore propose broad OA definitions 49 with the intent to refine them through "crowd-sourcing" from the OARSI membership via a WIKI 50 on the OARSI website. 
82
"Disease" refers to abnormalities of the structure and function of body organs and systems that 83 can be specifically identified and described by reference to certain biological, chemical or other 84 evidence [5] . A disease has specific properties and a recurring identity in whichever setting it 5 appears. Because a particular disease is assumed to be universal in its form, progress and 86 content [5], we seek here to define OA as disease, not by patient phenotype but rather by its 87 universal form.
89
An "illness" refers to the human response to disease [5] . Cassell in 1978 described illness to 90 mean "what the patient feels when he goes to the doctor", and disease to mean "what he has on 91 the way home from the doctor's office"; in short, disease is something an organ has and illness 92 is something a person has (summarized by Helman [5]). The specific manifestations of illness 93 are likely to differ according to OA phenotype. Although they may coexist, and often do, it is 94 possible for disease to occur in the absence of illness. Like osteoporosis, OA may be manifest 95 by a prolonged period of musculoskeletal tissue abnormalities at a molecular but clinically silent 96 level that can precede the anatomic organ system disease and illness manifestations by years 97 or even decades ( Figure 1 ). Thus, very early OA would be characterized by an asymptomatic 98 disease state. It is common in OA that disease does not coincide with illness; definite 99 radiographic features of OA are often found in joints of persons without symptoms. In this sense, 100 the disease and its radiographic features could be considered risk factors for the illness. A 101 precedent exists in spondyloarthropathies for which preradiographic diagnostic disease criteria 102 were developed [6] that subsequently stimulated treatment trials [7] . By analogy, we hope that a 103 greater understanding and consensus regarding the disease versus illness aspects of OA would 104 similarly stimulate treatment trials for early OA.
106
There is much we do not know about the chronology of the OA trajectory from molecular 107 disease to anatomic disease to illness. As noted in Figure 1 , we posit that molecular 108 abnormalities may coexist with anatomic abnormalities in the absence of illness; we observe 109 this as radiographic or MRI abnormalities in the absence of symptoms. We also posit that 110 molecular abnormalities may coexist with illness in the absence of measurable anatomic 6 abnormalities; this may be due, for instance, to cartilage degradation products activating innate 112 immunity, subclinical synovitis and pain in the absence of discernible anatomic derangements 113 by the current imaging tools. Illness might also occur in the absence of discernible disease; if 114 truly OA related, then this could be due to a lack of sensitive enough biochemical and imaging 115 biomarker tools to detect disease. In OA, it will be challenging to confidently rule out disease at 116 early stages until we have sensitive tools for identifying the early molecular derangements of the 117 joint organ. Of course, any aspect of disease may coexist with illness [8].
119
In addition to illness and molecular and anatomic aspects of disease, there can be physiologic 120 aspects of disease ( Figure 2A ). It is said that anatomy studies the form, while physiology looks 
187
To date there is only scant evidence to support the ability of these pathways to distinguish OA 188 uniquely from other arthritides, such as rheumatoid arthritis [34] . This important knowledge gap 9 needs to be a focus of future research. However, there are data to suggest that cartilage from 190 different joint sites differ in their biochemical constituents [35] and that therefore, it may 191 ultimately be possible to identify molecular OA according to specific joint sites.
193
We considered the term metabolic to describe the molecular phase of the OA process. Although 194 the term metabolic is attractive for its ability to encompass the concept of joint tissue the causes of OA and allow OARSI researchers to share and update this information. We hope 419 that the exercise of posting this draft taxonomy of OA to the web and engaging the membership 420 in its refinement will be a start to an expanding range of information on the disease and illness 421 of OA that can facilitate and invigorate the research enterprise. 
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